BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials

By afschroeder • April 1, 2026

Hecht JR, Molina JR, Liechty K, Welling TH, Grierson PM, Patel SP, Kirtane K, Morelli MP, Locke FL, Maloney DG, Punekar SR, Nikiforow S, Lin Y, Ulrickson M, Specht JM, Lozac'hmeur A, Osterman CK, Garde RJ, Rangel GA, Ng EW, Welch JS, Tebbets JC, Go WY, Simeone DM. BASECAMP-1 screening study: a model for efficient enrolment in precision oncology clinical trials. BMJ Oncol. 2026 Mar 27;5(1):e001033. doi: 10.1136/bmjonc-2025-001033. PMID: 41918932; PMCID: PMC13034198.

Tags: cell therapy, Clinical Trial, Hematology/Oncology, metastatic cancer, Publications, Solid tumour

Related Posts

Plain language summary of the LOGIC 2 study: Encorafenib, binimetinib, plus a third drug for people with BRAF V600-mutant melanoma

Dummer R, Sandhu S, Miller WH Jr, Butler MO, Taylor MH, Heinzerling L, Blank CU, Couselo EM, Burris HA 3rd, Postow MA, Chmielowski B, Middleton[...]

A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

Johnson ML, Smit EF, Felip E, Ramalingam SS, Ahn MJ, Tsao A, Johnson BE, Offin M, Hussein M, Dagogo-Jack I, Goldman JW, Clarke JM, Negrao[...]

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder[...]